Long-term outcomes of eltrombopag plus cyclosporine A in eltrombopag-exposed patients with glucocorticoid-resistant or -dependent primary immune thrombocytopenia: a prospective, multicenter, single-arm, phase II study with extended follow-up. (PubMed, Front Immunol) - Sep 25, 2026 - P4 | "AE-related treatment discontinuation was an important contributor to treatment failure, and the occurrence of two fatal infections highlights the need for careful patient selection and close infection monitoring. The re-challenge and baseline bleeding-score findings were exploratory and require validation in larger, controlled studies."
Journal • P2 data • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Infectious Disease • Thrombocytopenia • Thrombocytopenic Purpura
|
|
Changle Huang; Fangqi Cheng; Huifang Jiang; Jiayue Qin; Jie Jin; Jin Lai; Lihong Cao; Xuwei Shao; Yuhui Yuan
|